Sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients

This study is the first to show that a DPP-4 inhibitor, sitagliptin, reduces inflammatory cytokines and improves the unfavorable M1/M2-like phenotypes of peripheral blood monocytes in Japanese type 2 diabetic patients (Metabolism – Clinical and Experimental)